MZL
MCID: MRG003
MIFTS: 57

Marginal Zone B-Cell Lymphoma (MZL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Marginal Zone B-Cell Lymphoma

MalaCards integrated aliases for Marginal Zone B-Cell Lymphoma:

Name: Marginal Zone B-Cell Lymphoma 38 12 15 73
Marginal Zone Lymphoma 12 53
Mucosa-Associated Lymphoid Tissue Lymphoma 73
Mzl 53

Classifications:



External Ids:

Disease Ontology 12 DOID:0050748

Summaries for Marginal Zone B-Cell Lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue.

MalaCards based summary : Marginal Zone B-Cell Lymphoma, also known as marginal zone lymphoma, is related to primary cutaneous marginal zone b-cell lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with Marginal Zone B-Cell Lymphoma is MALT1 (MALT1 Paracaspase), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Amoxicillin and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Marginal Zone B-Cell Lymphoma

Diseases related to Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 230)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous marginal zone b-cell lymphoma 34.5 BCL10 IRF4 MALT1
2 nodal marginal zone b-cell lymphoma 34.3 BCL2 BCL6 MALT1
3 splenic marginal zone lymphoma 33.0 BCL6 BIRC3 CD5 MALT1
4 lymphoma, mucosa-associated lymphoid type 32.3 BCL10 BCL2 BCL6 BIRC3 CCND1 CD5
5 lymphoma 31.7 BCL10 BCL2 BCL6 CCND1 MALT1
6 b-cell lymphomas 30.7 BCL10 BCL2 BCL6 BIRC3 CCND1 CD5
7 composite lymphoma 30.6 BCL6 CD5
8 anemia, autoimmune hemolytic 30.5 C1S CD40LG CD5
9 peripheral t-cell lymphoma 30.4 BCL6 CD5 MME
10 lymphosarcoma 30.4 BCL6 CD5 CD79A
11 immunoglobulin a deficiency 1 30.2 CD40LG CD79A
12 cryoglobulinemia, familial mixed 30.1 CD40LG CD5
13 cryoglobulinemia 30.1 CD40LG CD5 CD79A
14 extramedullary plasmacytoma 30.1 BCL2 CCND1
15 autoimmune lymphoproliferative syndrome, type v 30.0 BCL2 BCL6 CD5
16 mantle cell lymphoma 30.0 BCL2 BCL6 CCND1 CD5 MALT1 MME
17 lymphocytic leukemia 29.9 BCL2 CD5 MME MYD88
18 glomerulonephritis 29.9 C1S CD40LG CD79A
19 lymphoma, hodgkin, classic 29.9 BCL6 CD5 CD79A MME
20 cll/sll 29.6 CCND1 CD5 MME
21 burkitt lymphoma 29.6 BCL2 BCL6 BIRC3 CD40LG MME
22 leukemia, chronic lymphocytic 29.5 BCL10 BCL2 BCL6 CCND1 CD40LG CD5
23 follicular lymphoma 29.4 BCL10 BCL2 BCL6 CCND1 IRF4 MME
24 diffuse large b-cell lymphoma 29.4 BCL6 CD5 CD79A FOXP1 IRF4 KMT2D
25 lymphoma, non-hodgkin, familial 28.4 BCL10 BCL2 BCL6 BIRC3 CCND1 CD5
26 nodal marginal zone lymphoma 11.5
27 histiocytosis 10.5
28 amyloidosis 10.5
29 hepatitis 10.5
30 arthritis 10.4
31 plasmacytoma 10.4
32 rheumatoid arthritis 10.4
33 hepatitis c 10.4
34 macroglobulinemia 10.4
35 hemolytic anemia 10.3
36 hepatitis c virus 10.3
37 leukemia 10.3
38 chromosomal triplication 10.2 BCL6 MALT1
39 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.2 BCL2 BCL6
40 primary cutaneous diffuse large b-cell lymphoma, leg type 10.2 IRF4 MYD88
41 systemic lupus erythematosus 10.2
42 langerhans cell histiocytosis 10.2
43 gastric cancer 10.2
44 hepatitis b 10.2
45 microinvasive gastric cancer 10.2
46 chlamydia 10.2
47 hairy cell leukemia 10.2
48 adenocarcinoma 10.2
49 thyroiditis 10.2
50 lupus erythematosus 10.2

Graphical network of the top 20 diseases related to Marginal Zone B-Cell Lymphoma:



Diseases related to Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Marginal Zone B-Cell Lymphoma

GenomeRNAi Phenotypes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.78 BCL10 BCL2 BIRC3 CD40LG MALT1 MYD88
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.78 BCL10 BCL2 BIRC3 CD40LG MALT1 MYD88

MGI Mouse Phenotypes related to Marginal Zone B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 BCL10 BCL2 BCL6 BIRC3 CCND1 CD40LG
2 cellular MP:0005384 10.06 BCL10 BCL2 BCL6 BIRC3 CCND1 CD40LG
3 cardiovascular system MP:0005385 9.97 BCL2 BCL6 BIRC3 CCND1 CD40LG KMT2D
4 homeostasis/metabolism MP:0005376 9.9 BCL2 BCL6 BIRC3 CCND1 CD40LG CD79A
5 immune system MP:0005387 9.8 BCL10 BCL2 BCL6 BIRC3 CCND1 CD40LG
6 neoplasm MP:0002006 9.1 BCL2 CCND1 CD79A IRF4 KMT2D MYD88

Drugs & Therapeutics for Marginal Zone B-Cell Lymphoma

Drugs for Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 490)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 26787-78-0 33613
2
Metronidazole Approved Phase 4,Phase 3,Phase 2 443-48-1 4173
3
Clarithromycin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81103-11-9 84029
4
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
5
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 135968-09-1
6
Esomeprazole Approved, Investigational Phase 4,Phase 2 161796-78-7, 119141-88-7 4594 9579578
7
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 52-24-4 5453
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
9 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Proton Pump Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
17 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
19 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Antimalarials Phase 4,Phase 2,Phase 1
26
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
27
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 174722-31-7 10201696
28
Vidarabine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 24356-66-9 32326 21704
29
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
30
Pixantrone Approved, Investigational Phase 3 144510-96-3
31 Orange Approved Phase 3
32
Ciprofloxacin Approved, Investigational Phase 3,Not Applicable 85721-33-1 2764
33
Iron Approved Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6 23925
34
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
35
Ofloxacin Approved Phase 3 82419-36-1 4583
36
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
37
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 55-98-1 2478
38
Idarubicin Approved Phase 3 58957-92-9 42890
39
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
40
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
41
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
42
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
43
Doxorubicin Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
44
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
45
Prednisone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
46
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
47
Lenalidomide Approved Phase 3,Phase 2,Phase 1 191732-72-6 216326
48
Carboplatin Approved Phase 2, Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
49
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
50
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541

Interventional clinical trials:

(show top 50) (show all 704)
# Name Status NCT ID Phase Drugs
1 10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection Completed NCT02959255 Phase 4 Esomeprazole
2 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
3 High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection Recruiting NCT02553083 Phase 4 Nexium 40 mg;amoxicillin 1.5 gr;doxycycline 200 mg;Nexium 20 mg;clarythromicin 500 mg;amoxicillin 1gr
4 Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
5 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Unknown status NCT00551239 Phase 3 fludarabine phosphate;pixantrone dimaleate
7 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
9 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
10 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
11 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
12 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
13 Combination Chemotherapy With or Without Interferon Alfa in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
14 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
15 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
16 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
17 Low-Dose Radiation Therapy in Treating Patients With Follicular or Marginal Zone Non-Hodgkin's Lymphoma Completed NCT00310167 Phase 3
18 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma Completed NCT01701232 Phase 3
19 A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Completed NCT02302170 Phase 3
20 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
21 Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn Completed NCT00255190 Phase 3 Dexlansoprazole MR;Dexlansoprazole MR
22 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
23 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3 Bendamustine;Standard chemotherapy CHOP + Ritiximab
24 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
25 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
26 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
27 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
28 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
29 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
30 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
31 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
32 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
33 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
34 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
35 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
36 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
37 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
38 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
39 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
40 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
41 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3 levofloxacin
42 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
43 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
44 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
45 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
46 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
47 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
48 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
49 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
50 Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease Completed NCT00003414 Phase 3 busulfan;cyclophosphamide;cyclosporine

Search NIH Clinical Center for Marginal Zone B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Marginal Zone B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Marginal Zone B-Cell Lymphoma

Anatomical Context for Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Marginal Zone B-Cell Lymphoma:

41
B Cells, Bone, Bone Marrow, T Cells, Lung, Liver, Breast

Publications for Marginal Zone B-Cell Lymphoma

Articles related to Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 732)
# Title Authors Year
1
Pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymph tissue: A case report and literature review. ( 29519992 )
2018
2
Meningeal marginal zone B-cell lymphoma: The meningioma trap. ( 29331570 )
2018
3
Isolated superior oblique muscle extranodal marginal zone B cell lymphoma: case report. ( 29755275 )
2018
4
Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma. ( 29805758 )
2018
5
A case report of unusual cavity presentation of pulmonary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. ( 29979424 )
2018
6
A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL). ( 30254190 )
2018
7
Antiphospholipid antibodies associated with nodal marginal zone lymphoma and its progression to diffuse large B-cell lymphoma-A case report. ( 30385086 )
2018
8
Burden of illness of follicular lymphoma and marginal zone lymphoma. ( 30315345 )
2018
9
Recurrent autoimmune hemolytic anemia in splenic marginal zone lymphoma. ( 30181837 )
2018
10
A Rare Case of Composite Dural Extranodal Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. ( 29740389 )
2018
11
Splenic marginal zone lymphoma leads to sinistral portal hypertension. ( 30549195 )
2018
12
High Frequency of MYD88 L265P Mutation in Primary Ocular Adnexal Marginal Zone Lymphoma and Its Clinicopathologic Correlation: A Study From a Single Institution. ( 30444439 )
2018
13
Dural based marginal zone lymphoma in a patient with sarcoidosis: a case report. ( 30476667 )
2018
14
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. ( 30407629 )
2018
15
Simultaneous Occurrence of Rosai-Dorfman Disease and Nodal Marginal Zone Lymphoma in a Patient with Sjögren's Syndrome. ( 30305966 )
2018
16
IgG4 expression in cutaneous marginal zone lymphoma with plasmacytic differentiation and localized amyloid deposition: A useful clue to cutaneous origin. ( 30306118 )
2018
17
Hyperviscosity syndrome in splenic marginal zone lymphoma. ( 30309878 )
2018
18
Validation of the Marginal Zone Lymphoma International Prognostic Index. ( 30310985 )
2018
19
Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. ( 30312133 )
2018
20
IRTA1 and MNDA Expression in Marginal Zone Lymphoma: Utility in Differential Diagnosis and Implications for Classification. ( 30346478 )
2018
21
Lymphomagenic properties of a HIV p17 variant derived from a splenic marginal zone lymphoma occurred in a HIV-infected patient. ( 30261551 )
2018
22
Correction: The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP. ( 30214692 )
2018
23
PD1hi cells associate with clusters of proliferating B-cells in marginal zone lymphoma. ( 30219078 )
2018
24
Efficacy and safety of rituximab plus bendamustine for gastric marginal zone lymphoma. ( 30234387 )
2018
25
Pulmonary extranodal marginal zone lymphoma that presented with macroglobulinemia and marked plasmacytic cell proliferation carrying the t(14;18)(q32;q21)/MALT1-immunoglobulin heavy-chain fusion gene in pleural fluid. ( 30089750 )
2018
26
Concurrent Mycobacterium tuberculosis infection and nodal marginal zone lymphoma. ( 29731142 )
2018
27
« Malignant » Rosacea as a sign of systemic marginal zone lymphoma. ( 28776782 )
2018
28
Idelalisib and Rituximab in 17p Deletion-Positive Splenic Marginal Zone Lymphoma. ( 29523661 )
2018
29
Bone marrow-derived mesenchymal stem/stromal cells from patients with splenic marginal zone lymphoma are intrinsically impaired and influence the malignant B-cells. ( 29966468 )
2018
30
Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA. ( 30042829 )
2018
31
Neuroendocrine Neoplasia in Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma) of the Lung: A Case Report and Immunohistochemistry Analysis of Eight Pulmonary MALT Lymphomas. ( 29673288 )
2018
32
IgG4 Expression in Primary Cutaneous Marginal Zone Lymphoma: A Multicenter Study. ( 28151793 )
2018
33
Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma. ( 28771659 )
2018
34
Ocular adnexal marginal zone lymphoma of mucosa-associated lymphoid tissue. ( 28939925 )
2018
35
Extranodal Marginal Zone Lymphoma of the Central Nervous System. ( 29103980 )
2018
36
Effective management strategies for patients with marginal zone lymphoma. ( 29260925 )
2018
37
Painless Vulvar Masses as Initial Manifestation of Marginal Zone Lymphoma. ( 29271861 )
2018
38
Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and-wait strategy after complete resection. ( 29286565 )
2018
39
Marginal Zone Lymphoma of the Entire Gastrointestinal Tract. ( 29311729 )
2018
40
Orbital Extranodal Marginal Zone Lymphoma Following Radiotherapy: A Report of 2 Cases. ( 29319640 )
2018
41
Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review. ( 29340761 )
2018
42
Combined intraocular and systemic rituximab for ocular lymphoproliferative disorder with extranodal marginal zone lymphoma-type morphology after heart transplant. ( 29408337 )
2018
43
Marginal zone lymphoma of palatine tonsil with prominent plasmacytic differentiation: A CARE-compliant article and review of literature. ( 29480878 )
2018
44
Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone Lymphoma. ( 29481902 )
2018
45
Sustained response to lenalidomide for early relapsed marginal zone lymphoma. ( 29496374 )
2018
46
Primary hepatic marginal zone lymphoma: A rare coincidence. ( 29519669 )
2018
47
Primary Marginal Zone Lymphoma of the Lung and Organizing Pneumonia: A Diagnostic Challenge. ( 29527863 )
2018
48
Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. ( 29566563 )
2018
49
Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. ( 29572581 )
2018
50
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. ( 29628774 )
2018

Variations for Marginal Zone B-Cell Lymphoma

Expression for Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Marginal Zone B-Cell Lymphoma.

Pathways for Marginal Zone B-Cell Lymphoma

Pathways related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.66 BCL10 BCL2 BCL6 BIRC3 C1S CCND1
2
Show member pathways
13.19 BCL2 BCL6 BIRC3 CCND1 CD40LG IRF4
3
Show member pathways
13.08 BCL10 BCL2 CCND1 CD79A MALT1 MYD88
4
Show member pathways
12.54 BCL2 BIRC3 CD40LG TNFAIP3
5
Show member pathways
12.51 BCL10 CD40LG MALT1 MYD88 TNFAIP3
6
Show member pathways
12.49 BCL10 CD40LG CD79A MALT1
7
Show member pathways
12.45 BCL2 BIRC3 CD40LG MYD88 TNFAIP3
8
Show member pathways
12.31 BCL10 CD40LG IRF4 MALT1
9 12.15 BCL2 CCND1 MYD88 TNFAIP3
10
Show member pathways
12.14 BCL10 BCL6 CD79A IRF4 MALT1
11
Show member pathways
12.08 BCL2 BIRC3 CD40LG MYD88
12 12.07 BCL10 BCL6 CD40LG CD79A IRF4 MALT1
13 12.03 BCL10 BCL2 MALT1 MYD88
14 11.9 BCL10 BCL2 BIRC3 CD40LG MALT1 TNFAIP3
15 11.87 CD5 CD79A MME
16 11.86 BCL2 BCL6 CCND1
17
Show member pathways
11.85 BCL2 BIRC3 TNFAIP3
18 11.79 BCL2 BCL6 CCND1 IRF4
19 11.75 BCL2 BIRC3 CCND1
20 11.66 BCL2 BIRC3 CCND1
21
Show member pathways
11.62 BCL2 BIRC3 CD40LG
22 11.61 MALT1 MYD88 TNFAIP3
23 11.54 BCL6 CD40LG IRF4
24
Show member pathways
11.53 BIRC3 CCND1 CD40LG
25 11.35 BCL6 CD40LG CD5 MME
26 11.15 BCL10 BCL2 BIRC3 CD40LG MALT1 MYD88
27 11.11 BIRC3 CD40LG TNFAIP3
28 10.94 BCL10 MALT1 TNFAIP3

GO Terms for Marginal Zone B-Cell Lymphoma

Cellular components related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.35 BCL10 BCL2 BIRC3 MALT1 MYD88
2 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.98 BCL10 BCL2 BIRC3 MYD88 TNFAIP3
2 inflammatory response GO:0006954 9.9 BCL6 CD40LG MYD88 TNFAIP3
3 negative regulation of apoptotic process GO:0043066 9.85 BCL2 BCL6 BIRC3 CD40LG MALT1 MYD88
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.78 BCL10 BIRC3 MALT1 MYD88
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.76 BCL10 CD40LG MALT1 MYD88
6 protein complex oligomerization GO:0051259 9.72 BCL10 MALT1 TNFAIP3
7 cytokine-mediated signaling pathway GO:0019221 9.72 BCL2 BCL6 CCND1 IRF4 MYD88
8 positive regulation of protein ubiquitination GO:0031398 9.71 BCL10 BIRC3 MALT1
9 regulation of apoptotic process GO:0042981 9.65 BCL10 BCL2 BCL6 BIRC3 MALT1
10 positive regulation of T cell activation GO:0050870 9.61 BCL10 MALT1
11 lipopolysaccharide-mediated signaling pathway GO:0031663 9.61 BCL10 MALT1 MYD88
12 response to iron ion GO:0010039 9.59 BCL2 CCND1
13 immunoglobulin mediated immune response GO:0016064 9.58 BCL10 MYD88
14 B cell proliferation GO:0042100 9.58 BCL2 CD40LG CD79A
15 negative regulation of B cell apoptotic process GO:0002903 9.57 BCL6 FOXP1
16 regulation of tumor necrosis factor production GO:0032680 9.56 FOXP1 MYD88
17 response to fungus GO:0009620 9.52 BCL10 MALT1
18 regulation of T cell receptor signaling pathway GO:0050856 9.51 BCL10 MALT1
19 regulation of germinal center formation GO:0002634 9.49 BCL6 TNFAIP3
20 B cell differentiation GO:0030183 9.46 BCL2 BCL6 CD40LG CD79A
21 regulation of inflammatory response GO:0050727 9.26 BCL6 BIRC3 FOXP1 MYD88
22 response to molecule of bacterial origin GO:0002237 8.8 BCL10 MALT1 TNFAIP3

Molecular functions related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.67 BCL10 BCL2 CCND1 IRF4
2 protease binding GO:0002020 9.56 BCL10 BCL2 MALT1 TNFAIP3
3 identical protein binding GO:0042802 9.56 BCL10 BCL2 BCL6 C1S FOXP1 MALT1
4 kinase activator activity GO:0019209 9.32 BCL10 MALT1
5 protein self-association GO:0043621 9.02 BCL10 FOXP1 MALT1 MYD88 TNFAIP3
6 protein binding GO:0005515 10.06 BCL10 BCL2 BCL6 BIRC3 C1S CCND1

Sources for Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....